Lv6
2058 积分 2025-05-09 加入
SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in China
1天前
已完结
A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
1天前
已完结
Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris
1个月前
已完结
Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China
1个月前
已完结
A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
1个月前
已完结
A Randomized Trial of Etanercept as Monotherapy for Psoriasis
1个月前
已完结
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
1个月前
已完结
Comparison of Biologics and Oral Treatments for Plaque Psoriasis
1个月前
已完结
Anti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage
1个月前
已完结
Efficacy and safety of PD‐L1 blockade envafolimab as neoadjuvant treatment in mismatch repair‐deficient, locally advanced colorectal cancer: An open‐label, single‐arm study
1个月前
已完结
皖公网安备34019202002308
